1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2017-2028)
2.2 Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2017-2022)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2023-2028)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2017-2022)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2017-2022)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2021
3.5 Drugs for Non-Small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2017-2022)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2023-2028) 5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2017-2022)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type
6.2.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
6.2.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
6.2.3 North America Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application
6.3.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
6.3.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
6.3.3 North America Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country
6.4.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
6.4.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada 7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type
7.2.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
7.2.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
7.2.3 Europe Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application
7.3.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
7.3.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
7.3.3 Europe Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country
7.4.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
7.4.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type
8.2.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application
8.3.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region
8.4.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type
9.2.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
9.2.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
9.2.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application
9.3.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
9.3.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
9.3.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country
9.4.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
9.4.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type
10.2.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application
10.3.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country
10.4.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Developments
11.3 Menarini
11.3.1 Menarini Company Details
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.3.5 Menarini Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.4.5 Sanofi Recent Developments
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.5.5 Ziopharm Oncology Recent Developments
11.6 Alchemia
11.6.1 Alchemia Company Details
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.6.5 Alchemia Recent Developments
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.7.5 Amgen Recent Developments
11.8 Apotex
11.8.1 Apotex Company Details
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.8.5 Apotex Recent Developments
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Details
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.9.5 BioMarin Pharmaceutical Recent Developments
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Details
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.10.5 CellAct Pharma Recent Developments
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Details
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.11.5 Cerulean Pharma Recent Developments
11.12 Cipla
11.12.1 Cipla Company Details
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.12.5 Cipla Recent Developments
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Details
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.13.5 Cornerstone Pharmaceuticals Recent Developments
11.14 Curis
11.14.1 Curis Company Details
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.14.5 Curis Recent Developments
11.15 CytRx
11.15.1 CytRx Company Details
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.15.5 CytRx Recent Developments
11.16 Eli Lilly
11.16.1 Eli Lilly Company Details
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.16.5 Eli Lilly Recent Developments
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.17.5 Exelixis Recent Developments
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Details
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.18.5 Fresenius Kabi Recent Developments
11.19 Genentech
11.19.1 Genentech Company Details
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.19.5 Genentech Recent Developments
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Details
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.20.5 Hikma Pharmaceuticals Recent Developments
11.21 Hospira
11.21.1 Hospira Company Details
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.21.5 Hospira Recent Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Details
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.22.5 Intas Pharmaceuticals Recent Developments
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Details
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.23.5 Karyopharm Therapeutics Recent Developments
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Details
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.24.5 Kyowa Hakko Kirin Recent Developments
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Details
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.25.5 Ligand Pharmaceuticals Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
